Baseline CD4 cell count appears to modify the effect of HAART use on CXCL13 level, where higher CD4 was associated with a greater biomarker response to HAART. When stratifying by baseline CD4, a decrease of 34.8 (14.8–54.8) % was seen in CXCL13 in those with baseline CD4 cell count below 200 cells/μl; in contrast, a decrease of 48.2 (34.1–62.3)% was seen in those with baseline CD4 cell count at least 350 cells/μl.
Only one-third of study participants achieved immediate and sustained virologic responses. In the subgroup that did not achieve optimal HIV suppression, increases in CD4 cell number were still apparent, with significant reductions in serum sCD27 and sCD30 levels. Results of subgroup analyses suggest that the effects of HAART on serum biomarkers was most pronounced in those persons who were naïve to ART prior to HAART initiation, consistent with previous studies . Therefore, persons who have experienced therapeutic failure with prior nonfully suppressive ART regimens, with resultant accumulation of drug resistance, may have a decreased probability of immune normalization with subsequent regimens.
There is a paucity of data examining the effect of HAART on the biomarkers measured in this study, and no published study has measured this group of biomarkers simultaneously. Atlas et al.  and De Milito et al.  examined the effect of HAART on plasma sCD27 levels. Atlas et al. reported results from a study of 64 persons (primarily of African ethnicity living in Sweden) with mixed HIV-1 subtypes, who were ART-naive at HAART initiation and experienced effective viral responses to HAART. When comparing results from a subgroup infected with HIV-1 subtype B, the predominant viral subtype in North America, to our results, Atlas et al. showed a more modest 9% decrease in sCD27 levels. De Milito et al. found that HAART-induced significant and progressive reductions, but not normalization, of plasma sCD27 levels in 26 HIV-infected persons after 27 months.
The results of our study are consistent with a previous pilot study of 34 MACS participants that examined the effect of HAART on CXCL13 serum levels , which reported a 21% decrease in CXCL13 serum levels after 1 year of HAART. Our results, in a larger study population, demonstrated greater than 40% decreases in CXCL13 after 2–3 years of HAART. Interestingly, baseline CD4 cell count appeared to modify the effect of HAART use on CXCL13 level, with higher CD4 being associated a greater decrease in CXCL13 levels following HAART initiation. CXCL13 is produced by follicular helper T cells (TFH), which is the T-cell subset that interacts with activated germinal-center B cells in secondary lymphoid organs [35,42]. Little is known about the effect of HIV infection on TFH cells, or about how these cells are normally regulated. A recent study identified a novel regulatory CD8+ T-cell subset in mice, which can suppress the activity of TFH cells . When these CD8+ regulatory T cells were disrupted, this resulted in the enhanced production of auto-antibodies and in autoimmunity, and in a 10-fold increase in the size of germinal-center area . It is interesting to speculate that more advanced HIV disease, for which low CD4 number can act as a marker, results in a more pronounced loss of such regulatory T-cell subsets, making it more difficult for HAART to restore the activity of such cells and dampen TFH activity, thereby resulting in a less marked decrease in CXCL13 levels post HAART. Clearly, additional research is needed to better define the effect of HIV infection, and of HAART, on TFH cells and on potential regulatory T-cell subsets that may act on those cells.
Several studies have examined the association between HAART and hypergammaglobulinemia [47–50]. Overall, these studies report a reduction in IgG with HAART use, and in some cases, normalization. Our results are consistent with these prior studies, but show much more modest decreases in serum IgG levels. In a case–control study, Chong et al.  reported 65% lower IgG levels among virologic responders who were compared with an ART-untreated group. Notermans et al.  reported complete normalization of IgG in 13 persons with virologic responses to HAART after 1.5 years of therapy, using a population-based reference range determined for the specific methodology in the testing hospital. Jacobson et al.  and Redgrave et al.  reported findings that were fairly consistent with ours, noting significant decreases, but not normalization, of IgG levels in persons who achieved effective HAART responses, with 45% (Jacobson et al.) and 37% (Redgrave et al.) of IgG values continuing to exceed reference limits.
Our results indicate that serum CRP levels were unaffected by HAART, and in fact appear to increase over time following HAART initiation. A similar pattern was seen in a study by Lau et al. , who reported a general increase in CRP over time in untreated HIV-infected men in the MACS, with a 4.5 and 8% increase per year for men who remained AIDS-free and for men who progressed to AIDS, respectively.
Overall, these findings suggest that HAART resulted in near normalization of some biomarkers, whereas others continue to be markedly elevated post-HAART. It is possible that such sustained immune system alterations occurring among HAART recipients may lead to ongoing or new pathological processes. It is also possible that immune dysfunction is resolving slowly, and will eventually normalize over time, with resultant normalization in markers of immune activation and inflammation. However, our findings do not support this, in that we saw fairly consistent results between the two post-HAART measurements. Perhaps more extended longitudinal study of immune activation biomarkers among successfully treated HAART recipients is warranted, to determine whether and when full immune function is restored. It would be expected that the longer a state of chronic B-cell hyperactivation exists, the greater the risk for accumulation of genetic errors that can lead to the development of AIDS-related NHL. Therefore, even if immune normalization is ultimately achieved, it would be expected that the excess risk of NHL among HIV-infected persons would be reduced, but not eliminated, with HAART use. This is consistent with the results of epidemiologic studies, which have noted whereas HAART is associated with a decreased incidence of AIDS-NHL, a significant elevation in NHL risk remains in HIV-positive persons receiving HAART [31,32,51].
Previous studies have shown that although HAART results in viral suppression to undetectable levels in peripheral blood, viral eradication is not achieved, even after years of continuous therapy , and there is quick rebound of plasma viremia with therapy interruption. Viral persistence is thought to be the result of long-term survival of infected memory CD4 cells, permitting a steady-state low level of viral replication in lymphoid tissue that is not detectable in the peripheral blood . This low-level HIV replication may contribute to persisting B-cell hyperactivation in those on HAART. The progressive increases in serum CRP levels seen in this study suggest ongoing immune activation may continue post-HAART.
We found no apparent effect of HAART upon IL-6 levels. The SMART study, a study of HAART administration, with one arm based on minimizing drug use using target CD4 number (drug conservation arm) and another aiming at maximal suppression of HIV plasma levels (viral suppression arm), found that IL-6 levels increased by 30% over the first month of the trial in the drug conservation arm but were unchanged in the viral suppression arm, and also that the risk of death was associated with higher IL-6 levels at study entry . In another study, plasma IL-6 levels did not seem to change in most HAART recipients following initiation of treatment, except in those who developed immune restoration and inflammatory syndrome (IRIS), who showed an increase in plasma IL-6 post-HAART . IL-6 is a B-cell-stimulatory cytokine that is involved in promoting IgH class switching and also has antiapoptotic effects on B cells, effects that have the potential to promote the development of B-cell cancers. In addition, a persistent excess of IL-6 may promote nascent lymphoma clones through its anti-apoptotic effects. Therefore, even if levels of other cytokines are normalized in HAART recipients, there still may be increased risks for those forms of AIDS-related NHL that are associated with errors in IgH class switch DNA recombination, which may be promoted by IL-6. If this is true, one would expect to observe excess levels of those forms of AIDS-NHL associated with this genetic error among HAART-treated persons. In light of this, it is informative to note that whereas the incidence of EBV-associated AIDS-related NHLs has decreased in the first decade of the HAART era, the incidence of Burkitt's lymphoma has not decreased significantly .
Another potential source of error can occur with spurious events that cause transient increases in B-cell activation, such as responses to acute infection. Since effective HAART will potentially decrease the likelihood of acute infections, it is probable that acute infections will more likely occur prior to exposure to HAART.
Ultimately we would like to have been able to evaluate most closely those persons who developed AIDS-related NHL during the course of their infection and HAART treatment. However, with only 12 men this group developing AIDS-NHL, it was not possible to provide a formal analysis of this subgroup. Descriptive analyses suggest the NHL subgroup had a similar HAART response to that seen in the larger group of HIV-infected persons, with substantial decreases, but not normalization, of biomarker levels following HAART. Further studies in a larger NHL group are needed to support these findings.
Overall, our study indicates that HAART is associated with reductions in, but not normalization of, some markers of B-cell activation. None of the biomarkers were completely normalized in all individuals; 65% of individuals continued to have at least one elevated biomarker 2–3 years after HAART initiation. It is clear that good virologic and CD4 responses to HAART do not necessarily equate with normalization of these B-cell activation-associated molecules. Perhaps, markers of immune recovery should include routine assessment of markers of both B-cell and T-cell function. Finally, our results suggest that an altered immune environment still exists 2–3 years after HAART initiation, which has the potential to contribute to the increased risk of AIDS-related NHL that persists in those receiving effective antiretroviral treatment.
We would like to thank the UCLA-MACS participants, who have made this and many other studies of HIV disease possible. We also thank Larry Magpantay and Guadalupe Peña for technical assistance. This work was supported, in part, by funds from the National Cancer Institute (CA-57152, CA-73475). This work was carried out in the facilities of the UCLA AIDS Institute, which were supported, in part, by funds from the James B. Pendleton Charitable Trust and the McCarthy Family Foundation. Data in this manuscript were collected by the Multicenter AIDS Cohort Study (MACS) with centers (Principal Investigators) at The Johns Hopkins Bloomberg School of Public Health (Joseph B. Margolick, Lisa P. Jacobson), Howard Brown Health Center, Feinberg School of Medicine, Northwestern University, and Cook County Bureau of Health Services (John P. Phair, Steven M. Wolinsky), University of California, Los Angeles (Roger Detels), and University of Pittsburgh (Charles R. Rinaldo). The MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute. UO1-AI-35042, 5-MO1-RR-00052 (GCRC), UO1-AI-35043, UO1-AI-35039, UO1-AI-35040, UO1-AI-35041. Website located at http://www.statepi.jhsph.edu/macs/macs.html.
Contributions to authorship: D.R. designed the study, performed laboratory studies, analyzed the results, and wrote the paper; R.D., E.C.B. and O.M.-M. designed the study and wrote the paper; L.J., F.P., D.P.W., C.R. and J.H.B. wrote the paper.
1. Schroff RW, Gottlieb MS, Prince HE, Chai LL, Fahey JL. Immunological studies of homosexual men with immunodeficiency and Kaposi's sarcoma. Clin Immunol Immunopathol 1983; 27:300–314.
2. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation
and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983; 309:453–458.
3. Martinez-Maza O, Crabb E, Mitsuyasu RT, Fahey JL, Giorgi JV. Infection with the human immunodeficiency virus (HIV
) is associated with an in vivo increase in B lymphocyte activation
and immaturity. J Immunol 1987; 138:3720–3724.
4. Birx DL, Redfield RR, Tencer K, Fowler A, Burke DS, Tosato G. Induction of interleukin-6 during human immunodeficiency virus infection. Blood 1990; 76:2303–2310.
5. Breen EC, Rezai AR, Nakajima K, Beall GN, Mitsuyasu RT, Hirano T, et al
. Infection with HIV
is associated with elevated IL-6 levels and production. J Immunol 1990; 144:480–484.
6. Wright SC, Jewett A, Mitsuyasu R, Bonavida B. Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS
patients. J Immunol 1988; 141:99–104.
7. He B, Qiao X, Klasse PJ, Chiu A, Chadburn A, Knowles DM, et al
-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006; 176:3931–3941.
8. Moir S, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV
disease. J Allergy Clin Immunol 2008; 122:12–19, quiz 20-11.
9. Martin G, Tremblay MJ. HLA-DR, ICAM-1, CD40, CD40L, and CD86 are incorporated to a similar degree into clinical human immunodeficiency virus type 1 variants expanded in natural reservoirs such as peripheral blood mononuclear cells and human lymphoid tissue cultured ex vivo. Clin Immunol 2004; 111:275–285.
10. Amadori A, De Rossi A, Faulkner-Valle GP, Chieco-Bianchi L. Spontaneous in vitro production of virus-specific antibody by lymphocytes from HIV
-infected subjects. Clin Immunol Immunopathol 1988; 46:342–351.
11. Schnittman SM, Lane HC, Higgins SE, Folks T, Fauci AS. Direct polyclonal activation
of human B lymphocytes
by the acquired immune deficiency syndrome virus. Science 1986; 233:1084–1086.
12. Epeldegui M, Thapa DR, De la Cruz J, Kitchen S, Zack JA, Martinez-Maza O. CD40 ligand (CD154) incorporated into HIV
virions induces activation
-induced cytidine deaminase (AID) expression in human B lymphocytes
. PLoS One 2010; 5:e11448.
13. Martinez-Maza O, Breen EC. B-cell activation
and lymphoma in patients with HIV
. Curr Opin Oncol 2002; 14:528–532.
14. Epeldegui M, Widney DP, Martinez-Maza O. Pathogenesis of AIDS
lymphoma: role of oncogenic viruses and B cell activation
-associated molecular lesions. Curr Opin Oncol 2006; 18:444–448.
15. Widney DP, Breen EC, Boscardin WJ, Kitchen SG, Alcantar JM, Smith JB, et al
. Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV
infection. J Interferon Cytokine Res 2005; 25:702–706.
16. Breen EC, van der Meijden M, Cumberland W, Kishimoto T, Detels R, Martinez-Maza O. The development of AIDS
-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6. Clin Immunol 1999; 92:293–299.
17. Breen EC, Boscardin WJ, Detels R, Jacobson LP, Smith MW, O'Brien SJ, et al
. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter −592 C/C genotype. Clin Immunol 2003; 109:119–129.
18. Breen EC, Epeldegui M, Boscardin WJ, Widney DP, Detels R, Martinez-Maza O. Elevated levels of soluble CD44 precede the development of AIDS
-associated non-Hodgkin's B-cell lymphoma. AIDS
19. Breen EC, Fatahi S, Epeldegui M, Boscardin WJ, Detels R, Martinez-Maza O. Elevated serum soluble CD30 precedes the development of AIDS
-associated non-Hodgkin's B cell lymphoma. Tumour Biol 2006; 27:187–194.
20. Pluda JM, Venzon DJ, Tosato G, Lietzau J, Wyvill K, Nelson DL, et al
. Parameters affecting the development of non-Hodgkin's lymphoma
in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy
. J Clin Oncol 1993; 11:1099–1107.
21. Yawetz S, Cumberland WG, van der Meyden M, Martinez-Maza O. Elevated serum levels of soluble CD23 (sCD23) precede the appearance ofacquired immunodeficiency syndrome–associated non-Hodgkin's lymphoma
. Blood 1995; 85:1843–1849.
22. Schroeder JR, Saah AJ, Hoover DR, Margolick JB, Ambinder RF, Martinez-Maza O, et al
. Serum soluble CD23 level correlates with subsequent development of AIDS
-related non-Hodgkin's lymphoma
. Cancer Epidemiol Biomarkers Prev 1999; 8:979–984.
23. Widney D, Gundapp G, Said JW, van der Meijden M, Bonavida B, Demidem A, et al
. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV
infection and in AIDS
-associated lymphoma. Clin Immunol 1999; 93:114–123.
24. Widney DP, Gui D, Popoviciu LM, Saif JW, Breen EC, Huang X, et al
. Expression and function of the chemokie, CXCL13, and its receptor, CXCR5, in AIDS
-associated non-Hodgkin's lymphoma
Res Treatment 2010; 2010:9.
25. Kishimoto T. The biology of interleukin-6. Blood 1989; 74:1–10.
26. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006; 8(Suppl 2):S2.
27. Epeldegui M, Vendrame E, Martinez-Maza O. HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. Immunol Res
28. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation
-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102:553–563.
29. Pasqualucci L, Bhagat G, Jankovic M, Compagno M, Smith P, Muramatsu M, et al
. AID is required for germinal center-derived lymphomagenesis. Nat Genet 2008; 40:108–112.
30. Epeldegui M, Breen EC, Hung YP, Boscardin WJ, Detels R, Martinez-Maza O. Elevated expression of activation
induced cytidine deaminase in peripheral blood mononuclear cells precedes AIDS
-NHL diagnosis. AIDS
31. Biggar RJ. AIDS
-related cancers in the era of highly active antiretroviral therapy
. Oncology (Williston Park) 2001; 15:439–448, discussion 448-439.
32. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS
-related cancer and severity of immunosuppression in persons with AIDS
. J Natl Cancer Inst 2007; 99:962–972.
33. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation
. Curr Opin Immunol 2005; 17:275–281.
34. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998; 10:457–470.
35. Crotty S, Johnston RJ, Schoenberger SP. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol 2010; 11:114–120.
36. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al
. Inflammatory and coagulation biomarkers and mortality in patients with HIV
infection. PLoS Med 2008; 5:e203.
37. Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B, Gange SJ. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006; 166:64–70.
38. Toniatti C, Arcone R, Majello B, Ganter U, Arpaia G, Ciliberto G. Regulation of the human C-reactive protein gene, a major marker of inflammation and cancer. Mol Biol Med 1990; 7:199–212.
39. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38:189–197.
40. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS
Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126:310–318.
41. Infection DHJKFFPoCPftToH. Guidelines for the use of antiretroviral agents in HIV
-infected adults and adolescents. In 2006.
42. Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, Forster R. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000; 192:1545–1552.
43. Phillips AN, Staszewski S, Lampe F, Youle MS, Klauke S, Bickel M, et al
. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy
regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis 2002; 186:1086–1091.
44. Atlas A, Thanh Ha TT, Lindstrom A, Nilsson A, Alaeus A, Chiodi F, De Milito A. Effects of potent antiretroviral therapy
on the immune activation
marker soluble CD27 in patients infected with HIV
-1 subtypes A-D. J Med Virol 2004; 72:345–351.
45. De Milito A, Aleman S, Marenzi R, Sonnerborg A, Fuchs D, Zazzi M, Chiodi F. Plasma levels of soluble CD27: a simple marker to monitor immune activation
during potent antiretroviral therapy
-1-infected subjects. Clin Exp Immunol 2002; 127:486–494.
46. Kim HJ, Verbinnen B, Tang X, Lu L, Cantor H. Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance. Nature 2010; 467:328–332.
47. Chong Y, Ikematsu H, Yamamoto M, Chijiwa K, Ariyama I, Li W, et al
. Effect of highly active antiretroviral therapy
(HAART) on hypergammaglobulinemia in HIV
infected patients. Kansenshogaku Zasshi 2001; 75:535–540.
48. Notermans DW, de Jong JJ, Goudsmit J, Bakker M, Roos MT, Nijholt L, et al
. Potent antiretroviral therapy
initiates normalization of hypergammaglobulinemia and a decline in HIV
type 1-specific antibody responses. AIDS
Res Hum Retroviruses 2001; 17:1003–1008.
49. Redgrave BE, Stone SF, French MA, Krueger R, James IR, Price P. The effect of combination antiretroviral therapy
on CD5 B- cells, B-cell activation
and hypergammaglobulinaemia in HIV
-1-infected patients. HIV
Med 2005; 6:307–312.
50. Jacobson MA, Khayam-Bashi H, Martin JN, Black D, Ng V. Effect of long-term highly active antiretroviral therapy
in restoring HIV
-induced abnormal B-lymphocyte function. J Acquir Immune Defic Syndr 2002; 31:472–477.
51. Grulich AE. AIDS
-associated non-Hodgkin's lymphoma
in the era of highly active antiretroviral therapy
. J Acquir Immune Defic Syndr 1999; 21(Suppl 1):S27–S30.
52. Noe A, Plum J, Verhofstede C. The latent HIV
-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother 2005; 55:410–412.
53. Calcaterra S, Cappiello G, Di Caro A, Garbuglia AR, Benedetto A. Comparative analysis of total and integrated HIV
-1 DNA in peripheral CD4 lymphocytes and monocytes after long treatment with HAART. J Infect 2001; 43:239–245.
54. Stone SF, Price P, Keane NM, Murray RJ, French MA. Levels of IL-6 and soluble IL-6 receptor are increased in HIV
patients with a history of immune restoration disease after HAART. HIV
Med 2002; 3:21–27.
55. Munoz A, Carey V, Taylor JM, Chmiel JS, Kingsley L, Van Raden M, Hoover DR. Estimation of time since exposure for a prevalent cohort. Stat Med 1992; 11:939–952.